In Vitro and In Silico Studies of Neolignans from Magnolia grandiflora L. Seeds against Human Cannabinoids and Opioid Receptors
-
Published:2023-01-27
Issue:3
Volume:28
Page:1253
-
ISSN:1420-3049
-
Container-title:Molecules
-
language:en
-
Short-container-title:Molecules
Author:
Pandey Pankaj1ORCID, Kumarihamy Mallika1, Chaturvedi Krishna2ORCID, Ibrahim Mohamed A. M.1ORCID, Lambert Janet A.3, Godfrey Murrell2, Doerksen Robert J.3ORCID, Muhammad Ilias1
Affiliation:
1. National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA 2. Department of Chemistry and Biochemistry, The University of Mississippi, University, MS 38677, USA 3. Department of BioMolecular Sciences, Division of Medicinal Chemistry and Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA
Abstract
Magnolia grandiflora L. (Magnoliaceae) is a plant of considerable medicinal significance; its flowers and seeds have been used in various traditional remedies. Radioligand binding assays of n-hexane seeds extract showed displacement of radioligand for cannabinoid (CB1 and CB2) and opioid δ (delta), κ (kappa), and µ (mu) receptors. Bioactivity-guided fractionation afforded 4-O-methylhonokiol (1), magnolol (2), and honokiol (3), which showed higher binding to cannabinoid rather than opioid receptors in radioligand binding assays. Compounds 1–3, together with the dihydro analog of 2 (4), displayed selective affinity towards CB2R (Ki values of 0.29, 1.4, 1.94, and 0.99 μM, respectively), compared to CB1R (Ki 3.85, 17.82, 14.55, and 19.08 μM, respectively). An equal mixture of 2 and 3 (1:1 ratio) showed additive displacement activity towards the tested receptors compared to either 2 or 3 alone, which in turn provides an explanation for the strong displacement activity of the n-hexane extract. Due to the unavailability of an NMR or X-ray crystal structure of bound neolignans with the CB1 and CB2 receptors, a docking study was performed to predict ligand–protein interactions at a molecular level and to delineate structure-activity relationships (SAR) of the neolignan analogs with the CB1 and CB2 receptors. The putative binding modes of neolignans 1–3 and previously reported related analogs (4, 4a, 5, 5a, 6, 6a, and 6b) into the active site of the CB1 and CB2 receptors were assessed for the first time via molecular docking and binding free-energy (∆G) calculations. The docking and ∆G results revealed the importance of a hydroxyl moiety in the molecules that forms strong H-bonding with Ser383 and Ser285 within CB1R and CB2R, respectively. The impact of a shift from a hydroxyl to the methoxy group on experimental binding affinity to CB1R versus CB2R was explained through ∆G data and the orientation of the alkyl chain within the CB1R. This comprehensive SAR, influenced by the computational study and the observed in vitro displacement binding affinities, has indicated the potential of magnolia neolignans for developing new CB agonists for potential use as analgesics, anti-inflammatory agents, or anxiolytics.
Funder
National Institute of General Medical Sciences NIH COBRE CORE-NPN Research Core A, C USDA ARS co-operative NIST
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference43 articles.
1. Trends in GPCR drug discovery: New agents, targets and indications;Hauser;Nat. Rev. Drug Discov.,2009 2. Anti-obesity therapy with peripheral CB1 blockers: From promise to safe(?) practice;Quarta;Int. J. Obes.,2020 3. The case for peripheral CB(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications;Kunos;Br. J. Pharmacol.,2011 4. Soler-Cedeno, O., and Xi, Z.-X. (2022). Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge. Cells, 11. 5. Pandey, P., Roy, K.K., Liu, H., Ma, G., Pettaway, S., Alsharif, W.F., Gadepalli, R.S., Rimoldi, J.M., McCurdy, C.R., and Cutler, S.J. (2018). Structure-based identification of potent natural product chemotypes as cannabinoid receptor 1 inverse agonists. Molecules, 23.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|